Serina Therapeutics, Inc. SER
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Serina Therapeutics, Inc. (SER) is a healthcare company listed in the US with a market value of about $35M. In the twelve months to September 30, 2026 it had revenue of $255000 and net income of -$24M, a net margin of -9606.3%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -18% a year, a 5-year average ROIC of -638%.
About Serina Therapeutics
Serina Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $1M in 2017 to $130000 in 2025, a decline of about 25.7% a year. It was profitable in 1 of the last 9 years in our data. Its share count rose by 39% over three years (dilution for shareholders). It spends 10119% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $255000 | $130000 | $56000 | $3M | $34000 | $144000 | $361000 | $2M | $1M | $1M |
| Net income | -$24M | -$19M | -$11M | $5M | -$10M | -$9M | -$11M | -$12M | -$8M | -$7M |
| Free cash flow | -$23M | -$18M | -$17M | -$3M | — | — | -$8M | -$11M | -$8M | -$6M |
| EPS (diluted) | $-1.75 | $-1.91 | $-1.51 | $0.73 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
| Net margin | -9606.3% | -14755.4% | -19894.6% | 167.1% | -30770.6% | -6024.3% | -3009.7% | -703.4% | -537.4% | -468.7% |
| ROIC | — | -577.5% | -1548.4% | -0.2% | -604.2% | -457.4% | — | -375.0% | -119.3% | -72.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $9.50, 583% above the current price; targets range from $8.00 to $11.00; the consensus rating is “none”; expected EPS is $-1.58 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Serina Therapeutics pay a dividend?
Not currently.
Is Serina Therapeutics a good stock to buy?
We do not give buy or sell advice. Serina Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.